Lactobacillus gasseri CP2305

Lactobacillus gasseri CP2305 is a flagship proprietary, heat-inactivated postbiotic (lactic acid bacterium) discovered and developed by asahi-quality-and-innovations-aqi and asahi-group-foods, subsidiaries of asahi-group-holdings. Derived from decades of extensive research originating from Asahi’s calpis beverage brand, this scientifically validated strain is central to the company’s push into mood-altering and functional wellness products.

Formulation Advantages

Because CP2305 is heat-inactivated, it can withstand harsh formulation environments, including high-heat processing and high-water content. This makes it highly viable for the adult-soft-drinks category and other functional beverages where live probiotics typically fail to survive pasteurization.

Psychobiological and Health Benefits

CP2305 has been clinically demonstrated in human trials to link gut health to mental wellness and mood regulation. Scientific validation has shown that the strain provides distinct psychobiological and physical benefits, including:

• Alleviating daily mental stress and reducing anxiety.
• Enhancing the depth and quality of sleep.
• Improving intestinal health and modulating the gut microbiome by maintaining beneficial Bifidobacterium levels.
• Mitigating fatigue.
• Managing menopausal symptoms.

Strategic Applications

The GLP-1 Demographic

CP2305 is increasingly being positioned as a strategic solution for the demographic utilizing glp-1-medications. Because these medications significantly alter gut motility and disrupt the gut microbiome, consumers are seeking functional products to restore microbial balance and manage stress.

Clinical Substantiation

Asahi’s rigorous, scientifically validated approach to developing CP2305 serves as a powerful regulatory moat. By providing clinically substantiated benefits, the ingredient contrasts sharply with startup brands that rely on unverified plant-based adaptogens, effectively addressing the clinical-substantiation-gap in the modern functional food and beverage market.

Commercialization and B2B Strategy

Rather than restricting the ingredient to its own consumer packaged goods, Asahi is utilizing asahi-group-foods to distribute CP2305 globally as a B2B ingredient.

In 2024, Asahi signed an exclusive global distribution agreement with adm-wild-valencia (ADM) to scale CP2305 to food and beverage manufacturers across North America, Europe, and Asia. ADM is actively positioning CP2305 for better-for-you snacks, functional beverages, and supplements, explicitly noting its relevance as consumers draw tighter correlations between gut health and mental well-being in the age of GLP-1s.

This partnership is central to Asahi’s B2B ecosystem play, allowing the company to monetize its proprietary biotics while simultaneously gaining access to ADM’s botanical extracts for its own ingredient-stacking and functional-premiumization strategies.

The ingredient’s industry impact was formally recognized in late 2025, when CP2305 won “Functional Ingredient of the Year” at Gulfood Manufacturing and a “Health Innovation Award” at Food Ingredients Europe.